Axsome Therapeutics shares traded higher Friday as attention tightened on a near-term regulatory catalyst: the FDA’s April 30, 2026 target action date for the supplemental NDA seeking an Auvelity (AXS-05) label expansion into agitation associated with Alzheimer’s disease. With the decision less than two weeks away, the price action looks consistent with pre-event positioning in a catalyst-driven biotech name. (globenewswire.com)

Auvelity is already commercial, and approval in Alzheimer’s disease agitation would add a major new indication that could materially expand the drug’s addressable market and change Axsome’s longer-term revenue trajectory. The FDA granted Priority Review for the filing and set the April 30, 2026 PDUFA goal date, making the event a binary, high-impact swing factor for the stock into month-end. (globenewswire.com)

The rally also fits a supportive sell-side backdrop: Axsome’s consensus view remains strongly positive, and recent coverage has reiterated buy ratings and higher targets in April as the market handicaps the probability-weighted value of the potential label expansion. With AXSM already elevated into the decision window, volatility can increase as traders adjust positioning around any FDA commentary, scheduling updates, or last-minute expectations shifts. (investing.com)

Key near-term milestones include the April 30, 2026 FDA action date for Auvelity in Alzheimer’s disease agitation and the company’s next quarterly results (early May, with market calendars showing May 4, 2026). Any updates on launch readiness, payer dynamics, or prescriptions for the current portfolio could amplify moves as investors recalibrate expectations heading into the decision. (simplywall.st)